Current use and questions concerning intravesical bladder cancer group for superficial bladder cancer (Q33851144)

29 July 2017

1 reference

title

Current use and questions concerning intravesical bladder cancer group for superficial bladder cancer (English)

1 reference

29 July 2017

1 reference

Dalbagni G

1 reference

29 July 2017

Herr HW

series ordinal

1 reference

29 July 2017

publication date

1 February 2000

1 reference

Urologic Clinics of North America

29 July 2017

published in

1 reference

29 July 2017

1 reference

29 July 2017

1 reference

29 July 2017

page(s)

137-46,

1 reference

The significance of lamina propria invasion on the prognosis of patients with bladder tumors

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970241-X

7 January 2021

A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970241-X

7 January 2021

Bladder tumors invading the lamina propria (stage A/T1): influence of endovesical bacillus Calmette-Guérin therapy on recurrence and progression

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970241-X

7 January 2021

The response of patients with superficial bladder cancer to a second course of intravesical bacillus Calmette-Guerin

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970241-X

7 January 2021

Additional bacillus Calmette-Guérin therapy for recurrent transitional cell carcinoma after an initial complete response

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970241-X

7 January 2021

Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970241-X

7 January 2021

Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970241-X

7 January 2021

Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970241-X

7 January 2021

Bacillus Calmette-Guerin Therapy for High Risk Stage T1 Superficial Bladder Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970241-X

7 January 2021

Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970241-X

7 January 2021

Superficial bladder cancer: progression and recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970241-X

7 January 2021

Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970241-X

7 January 2021

Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970241-X

7 January 2021

Tumour progression and survival in patients with T1G3 bladder tumours: 15‐year outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970241-X

7 January 2021

Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970241-X

7 January 2021

Low Dose Pasteur Bacillus Calmette-Guerin Regimen in Stage T1, Grade 3 Bladder Cancer Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970241-X

7 January 2021

Significance of p53 overexpression in urinary bladder transitional cell carcinoma in situ before and after bacillus Calmette-Guérin treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970241-X

7 January 2021

Stage T1, grade 3 transitional cell carcinoma of the bladder: an unfavorable tumor?

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970241-X

7 January 2021

Intravesical immunoprophylaxis in recurrent superficial bladder cancer (Stage T1): multicenter trial comparing bacille Calmette-Guérin and interferon-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970241-X

7 January 2021

A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970241-X

7 January 2021

Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guérin therapy: correlation to clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970241-X

7 January 2021

A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970241-X

7 January 2021

Cancer statistics, 1999.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970241-X

7 January 2021

Correlation between p53 over expression and response to bacillus Calmette-Guerin therapy in a high risk select population of patients with T1G3 bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970241-X

7 January 2021

A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970241-X

7 January 2021

Improving the safety of BCG immunotherapy by dose reduction. Cooperative Group CUETO.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970241-X

7 January 2021

BCG versus epirubicin in the prophylaxis of multiple superficial bladder tumours: results of a prospective randomized study using modified treatment schemes

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970241-X

7 January 2021

Clinicopathological evaluation of repeated courses of intravesical bacillus Calmette-Guerin instillation for preventing recurrence of initially resistant superficial bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970241-X

7 January 2021

Improving the efficacy of BCG immunotherapy by dose reduction

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970241-X

7 January 2021

p53 status does not predict initial clinical response to bacillus Calmette-Guerin intravesical therapy in T1 bladder tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970241-X

7 January 2021

Bacillus Calmette-Guerin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: long-term results

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970241-X

7 January 2021

Intravesical Chemotherapy (Mitomycin C) versus Immunotherapy (Bacillus Calmette-Guérin) in Superficial Bladder Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970241-X

7 January 2021

Alternating mitomycin C and bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder. The Finnbladder Group

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970241-X

7 January 2021

Alternating mitomycin C and bacillus Calmette-Guerin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer. Finnbladder Group

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970241-X

7 January 2021

Evaluation of a low-dose intravesical bacillus Calmette-Guérin (Tokyo strain) therapy for superficial bladder cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970241-X

7 January 2021

Prognostic Factors in Patients Treated with Intravesical Bacillus Calmette-Guerin for Superficial Bladder Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970241-X

7 January 2021

Use of maintenance intravesical bacillus Calmette-Guérin (BCG), with or without intradermal BCG, in patients with recurrent superficial bladder cancer. Long-term follow-up of a randomized phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970241-X

7 January 2021

Reassessment of conservative management for stage T1N0M0 transitional cell carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970241-X

7 January 2021

10.1016/S0094-0143(05)70241-X

Identifiers

DOI

1 reference

29 July 2017

1 reference